2016). Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium.
To better stratify thromboprophylaxis in pregnancy, we aimed to estimate the individual probability (absolute risk) of gestational VTE associated with thrombophilia and whether these risk factors are independent of a family history of VTE in first-degree relatives.
We studied 243 women with first VTE during pregnancy and the puerperium, and 243 agematched normal women. Baseline incidence of VTE of 1:483 pregnancies in women Introduction Venous thromboembolism (VTE) is an important cause of maternal morbidity and mortality in the Western world [1] [2] [3] [4] . While the relative risk of VTE is increased several-fold in women during pregnancy, the absolute risk remains low. Estimates of the incidence of pregnancyassociated VTE vary from 1:500 to 1:1500 pregnancies with higher estimates in more recent reports (1:500 to 1:1000) [5] [6] [7] [8] [9] [10] .
VTE is a multicausal disorder, in which acquired and hereditary risk factors interact 11 .
Pregnancy is an acquired and independent risk factor for the development of VTE. The risk of VTE is five times higher in pregnant women than in non-pregnant women of similar age 7 .
Acquired risk determinants can significantly increase the thrombotic risk further during pregnancy and the puerperium. These include maternal age (≥35 years), caesarean section, obesity, high parity (four or more), infection, and a personal or family history of VTE 8;12-18 . Knowledge of the aetiology of VTE advanced with the discovery of several genetic polymorphisms that contribute to venous thrombosis. As acquired and innate risk factors interact it is important to quantify the influence of heritable thrombophilias on risk of thrombosis. In women with pregnancy-associated VTE, there are data for the risk associated with the heterozygous genotype of the G1691A polymorphism in the gene encoding factor V (factor V Leiden) and the heterozygous genotype of the G20210A polymorphism in the gene encoding prothrombin [19] [20] [21] . However, few data exist in pregnant women, in whom homozygosity of single polymorphism or compound heterozygous polymorphisms are present 19;22;23 . Moreover, previous reports on the risk calculation for deficiencies of antithrombin, protein C, and protein S may have led to an overestimation of the risk of thrombosis due to selection bias in family studies [24] [25] [26] [27] .
Limited data on the magnitude of the thrombosis risk associated with heritable thrombophilias and the interaction of risk factors has impeded the development of evidence-based risk stratification to guide thromboprophylaxis. Consequently there is a lack of consensus on thromboprophylaxis in national and international guidelines 21;28-32 . Therefore, assessment of the individual thrombotic risk during pregnancy and the puerperium is important to provide evidence-based thromboprophylaxis management, and impact on the disease burden. Current recommendations regarding prophylactic anticoagulation during this period, particularly in women with severe thrombophilia such as homozygous factor V Leiden mutation (FVL), are based on the absence or presence of a positive family history of VTE 21 .
The aim of our study was a) to estimate the individual probability (absolute risk) of gestational VTE due to thrombophilic risk factors, b) to examine whether these risk factors are independent of a positive family history of VTE in first-degree relatives, and c) to consider whether or not this approach would be suitable to improve thromboprophylaxis management.
We performed a comprehensive analysis of the risk factors associated with venous thrombosis in women during pregnancy and the puerperium to quantify the contribution of hereditary thrombophilias to the risk of VTE, and to examine whether these risk factors are independent of a positive family history of VTE in first-degree relatives. As age >35 years is a known risk factor, and because of demographic changes with increasing rates of older childbearing women, the absolute risk of thrombosis was stratified for age (<35 and ≥ 35 years).
Subjects
We retrospectively studied 243 consecutive women with a history of first VTE (patient group) during pregnancy or the puerperium (6 weeks postpartum) and 243 age-matched control women with at least one prior pregnancy and no history of venous thromboembolism. Three patients and one control woman were pregnant with twins.
The women with a history of thromboembolism were referred for treatment of venous thromboembolism, or were sent for consultation for prophylaxis by local hospitals to the Düsseldorf University Medical Center between January 1990 and December 2008.
None showed overt evidence of autoimmune or neoplastic disease. All participants underwent assessment of their coagulation parameters, with blood sampling at least 3 months postpartum or 3 months after the cessation of lactation to exclude any pregnancy-related alterations in coagulation and fibrinolysis. In addition, in the patient group, blood samples were taken at least 6 months after the VTE event to exclude any thrombosis-and/or inflammation-related effects on laboratory test results.
All women in the patient group had an objectively diagnosed episode of deep venous thrombosis (DVT) or pulmonary embolism (PE). DVT was diagnosed by Doppler ultrasonography, impedance plethysmography, computerized tomography, or nuclear magnetic resonance tomography during pregnancy and Doppler ultrasonography or X-ray venography after delivery. PE was diagnosed by computerized tomography, ventilationperfusion scanning or nuclear magnetic resonance tomography during pregnancy, and by computerized tomography, ventilation-perfusion scanning, or pulmonary angiography in the postpartum period.
The 243 control women with at least one previous pregnancy were recruited by the Heinrich Heine University Blood Donation Centre and matched for age with the 243 women with a history of VTE. Matching for age was performed at the time of blood sampling (maximum age difference allowed: 5 years), since plasma levels of coagulation factor activities change with age. After matching the mean age in patients was 37.8 years, in control women 37.7 (p=0.97). To avoid a referral bias, all women with prior evaluation of genetic risk factors were excluded. Women were also excluded if they suffered from antiphospholipid syndrome. The control women were from the same geographic region as the women with a history of VTE, but were unrelated to them. Personal histories were obtained from all women using a standardized questionnaire, documenting the presence or absence of thromboembolic disease.
The study was approved by the Ethics Committee of the Faculty of Medicine, Heinrich Heine University, Düsseldorf, and written informed consent was given by all women participating in this study.
Laboratory Tests
Samples of whole blood were collected in vacuum tubes containing 3.8% (wt/vol) sodium citrate in a 1:9 ratio (vol/vol) of anticoagulant to blood. Platelet-poor plasma was prepared by centrifugation at 2000g for 10 minutes. Antithrombin activity was analyzed immediately.
Plasma for determination of other parameters was stored at −80°C until analysis.
The activities of plasma proteins C and S were measured by means of a functional clotting assay (Instrumentation Laboratory, Milano, Italy), and free protein S antigen was determined by means of an ELISA Kit (Diagnostic International, Schriesheim, Germany). Antithrombin activity was measured using Berichrom (Siemens Healthcare, Eschborn, Germany). For screening of lupus anticoagulant, a lupus-sensitive aPTT (Siemens Healthcare, Eschborn, Germany) and the DRVV test (American Diagnostica, Greenwich, CT, USA) were used. For confirmation of positive results, a DRVVT confirm test (American Diagnostica, Greenwich, CT, USA) was performed. Cardiolipin and ß 2 -glycoprotein I antibodies were quantified using an ELISA assay (Orgentec Diagnostika, Mainz, Germany).
For diagnosis of protein C, protein S and antithrombin deficiencies, percentiles of activity or antigen levels were determined in the age-matched control women. The 5th percentiles were 6 as follows: antithrombin activity 90%, protein C activity 76%, protein S activity 56%, free protein S antigen 57%. Deficiencies were defined a posteriori as either mild or severe, as indicated in Table 3 . Reduced levels of antithrombin, protein C, protein S, and free protein S antigen were routinely confirmed using another blood sample drawn on a different occasion.
Measurements of antithrombin, protein C and protein S activity were performed in women without hormone intake (see tables for exact numbers). DNA was extracted from peripheral blood leukocytes according to standard protocols using the Chelex system (BIO-RAD, München, Germany) or the Qiagen system (Qiagen, Hilden, Germany). The presence or absence of factor V Leiden and the G20210A polymorphism in the prothrombin gene were identified using an allele-specific restriction-enzyme analysis 33;34 .
Statistical Analysis
The SAS statistical package (version 9.2, SAS Institute, Cary, NC, USA) was used for all statistical analyses. Standard procedures were used to calculate frequencies, means and standard deviations. Depending on the type of data, a Wilcoxon rank-sum test or a Fisher exact test (2-tailed) was used to compare the different groups. Relative risk was estimated using odds ratios. The calculation of relative risks of thrombophilic risk factors was performed with regard to the patient and control population as a whole, without stratification for age (<35 years/≥35 years). Absolute risks of VTE per delivery were calculated using a logistic regression procedure. This procedure takes into account that the baseline risk includes thrombophilic and nonthrombophilic women in order to avoid an overestimation of the absolute risk. For estimation of predictive values, e.g. absolute risk, age-dependent incidence rates of VTE were calculated: an incidence of one thromboembolic event in 741 deliveries in women <35 years and of one thromboembolic event in 483 deliveries in women Complete data for genetic analyses were obtained for all women in the patient group; however, some data on coagulation assays were incomplete due to logistical issues associated with their management (e.g., results of coagulation assays may have been obtained earlier than the required ≥ 3 months postpartum or after the cessation of lactation). Exact numbers of women included in each of the analyses are indicated in the tables. For calculation of odds ratios of homozygous carriers of factor V Leiden, individuals with heterozygous defects were excluded and vice versa (see Table 2 ).
Based on the Hardy-Weinberg equilibrium, the frequency of homozygous factor V Leiden carriers in the normal population was calculated as 153/100,000 and the frequency of compound heterozygous factor V Leiden and prothrombin G20210A polymorphisms as 183/100,000. The frequency of antithrombin and protein C deficiency in the normal population was assumed to be 20/100,000 35 and 300/100,000 36 , respectively.
Results

Patient Characteristics
Patient characteristics are presented in Table 1 .
Odds Ratios and Probability of Venous Thromboembolism Associated with Genetic Defects
Patients with heterozygous and homozygous factor V Leiden and heterozygous G20210A prothrombin gene polymorphisms had significantly increased odds ratios for VTE ( Table 2) .
Thirteen of 243 women with a history of VTE had a compound heterozygosity for both factor V Leiden and the G20210A prothrombin gene polymorphisms (estimated odds ratio 47).
Since no control woman had this combined defect, the estimated odds ratio was calculated based on the probability of a combined defect in the population using the prevalence of heterozygous defects according to the Hardy-Weinberg equilibrium ( Table 2) .
The corresponding age-dependent absolute risks of VTE per pregnancy for these heritable thrombophilias are higher in women aged ≥ 35 years than in women aged <35 years (Table 3) .
Odds Ratio and Probability of Venous Thromboembolism Associated with Endogenous Coagulation Inhibitor Deficiencies
Odds ratios and age-dependent absolute risks of VTE were calculated for both mild and severe deficiencies (Table 4 ). Mild antithrombin deficiency (<90% activity) was associated with no significant increase in odds ratio for VTE, whereas antithrombin activity of 60% or lower carried a considerably higher risk (odds ratio 49, 95% CI 11.50-204) (two patients with antithrombin deficiency type I). Decreased activities of protein C, and protein S or free protein S antigen concentration were associated with an increased odds ratio for VTE (Table   4 ). The prevalence of a positive family history of thrombosis in first-degree relatives was significantly higher among women with a history of VTE than among control women ( Table   2 ). For further evaluation, the risk of thrombosis in patients with heterozygous factor V Leiden, homozygous factor V Leiden, heterozygous G20210A prothrombin gene polymorphism, or compound heterozygous factor V Leiden and G20210A prothrombin gene polymorphisms was adjusted for a positive family history of VTE in first-degree relatives. This analysis did not yield a relevant decrease in odds ratios ( Table 2 ). In addition, we performed a multivariate analysis to assess interactions between genetic risk factors and a family history of thrombosis in first-degree relatives. No interaction was detectable for heterozygous factor V Leiden and for compound heterozygous factor V Leiden and G20210A prothrombin gene polymorphisms. Due to the low numbers of patients, no interaction analysis could be performed for homozygous factor V Leiden and for heterozygous G20210A prothrombin gene polymorphism.
Positive family history of venous thrombosis in association with thrombophilic risk factors
Discussion
There is marked inconsistency between national and international clinical guidelines for antenatal thromboprophylaxis in pregnant women with heritable thrombophilias 21;28-32 . This reflects varying estimates of thrombosis risk associated with these thrombophilias particularly incontemporary studies, lack of information on the interaction with a family history of VTE, and differing perceptions of the threshold of risk above which pharmacological prophylaxis is considered appropriate. In particular for some thrombophilias, especially antithrombin deficiency, there are concerns that older studies overestimate the risk 24;25 due to methodologic limitations including referral bias and objective diagnosis.
This study now addresses many of these issues and can inform management decision for the need of thromboprophylaxis by quantifying the influence of heritable thrombophilias on VTE risk during pregnancy and the puerperium, stratifying for age (<35 years and To date, there are limited data on the risk of pregnancy-associated VTE among unselected homozygous carriers of factor V Leiden G1691A. In this study, the odds ratio of 17.2 (95% CI 6.3-47, probability of thrombosis 3.37% in women aged ≥ 35 years) for VTE associated with homozygosity for factor V Leiden is in agreement with a systematic review of nine studies by Robertson et al. 37 , which assessed the risk of VTE in pregnant women with inherited thrombophilia, but not necessarily with a family history of VTE, and reported an odds ratio of 34 (probability of thrombosis 4.8%).
In contrast to these results obtained from unselected patients, a much higher risk was reported in women with previous VTE and in women with symptomatic relatives. Several familybased cohort studies found that women with homozygous factor V Leiden and a positive family history, but without a previous episode of VTE have a risk of 14.0% of developing a first VTE episode during pregnancy or the postpartum period 22;23;38 .
Our data show that a compound defect of heterozygous factor V Leiden and G20210A prothrombin gene polymorphisms is associated with a disproportionate increase in risk compared with the risk of either alone. The results confirm our previous data 19;20 but are in contrast to two previous small studies which showed that the risk of first VTE during pregnancy and the puerperium in compound heterozygous carriers of factor V Leiden and G20210A prothrombin gene polymorphisms is low and similar to that of single heterozygous carriers 23;39 . In view of these conflicting results, a multiplicative risk increase in combined defects may be a plausible estimate (e.g., odds ratio 20).
Regardless of the presence or the kind of thrombophilia, a positive family history of VTE increases the risk of VTE two-to fourfold 21;40 . In our study, only 10 of 17 women with VTE and homozygous factor V Leiden or compound heterozygous factor V Leiden andG20210A prothrombin gene polymorphisms had first-degree relatives with a history of venous thrombosis. Using a multivariate analysis, the relative risk of thrombosis associated with homozygous defects or compound heterozygous factor V Leiden and G20210A prothrombin gene polymorphisms was independent of a positive family history of VTE in first degree relatives. Because of the high risk of VTE in women with homozygous factor V Leiden or with compound heterozygous factor V Leiden and G20210A prothrombin gene polymorphisms, our data are the first to provide evidence to support the indication for routine antepartum thromboprophylaxis (with heparin) in unselected pregnant women with no prior history of VTE in the presence of these defects, even if the family history of VTE is negative.
The relevance -and, more specifically, the predictive value -of deficiencies of antithrombin or proteins C and S are controversial. The clinical relevance of quantitatively different deficiencies in particular is still an unsolved problem. We now present odds ratios and individual probabilities of pregnancy-associated VTE for different degrees of deficiencies. As anticipated, mild deficiencies (e.g., antithrombin activity <90 % or protein C activity <76%), which represent the majority of clinical cases, are associated with a less pronounced increase in risk as compared to severe deficiencies ( Table 4 ).
Much of our knowledge about the risk of VTE in pregnant and postpartum women with inhibitor deficiencies has been derived from family studies, which are likely to overestimate the risk for unselected women with these defects, particularly for those with mild deficiencies 24-27 . In these studies, the risk of thromboembolism among antithrombin-deficient pregnant women not receiving anticoagulant therapy was estimated at up to 40% (3 to 40% in the antenatal period, 0 to 20% in the puerperium). For pregnant women with abnormalities in the protein C and S system not receiving anticoagulant therapy, the risk of thrombosis during pregnancy ranged from 3 to 10% for protein C deficiency and from 0 to 6% for protein S deficiency. In postpartum women, the risk was 7 to 19% for protein C deficiency and 7 to 22% for protein S deficiency [24] [25] [26] [27] . In contrast to these results obtained from family studies, a much lower risk is found in unselected women 19;20 . Our data support these findings by confirming a lower risk of deficiencies of antithrombin, protein C and protein S in unselected women. The most likely explanation for the particularly high risk in women from thrombophilic families is that familial thrombophilia is caused by multigenic effects. Thus, in each of the families, several known and unknown risk factors of thrombosis may be present, leading to an overestimation of the single risk factor under study 11 . A strength of our study is that we, for the first time, provide estimates of the absolute risk of thrombosis according to age and thrombophilic defects, allowing for an individualized risk assessment as a basis for prophylactic treatment decisions. The age stratification takes into account the demographic changes in the society with increasing rates of childbearing women ≥ 35 years of age.
A possible limitation of our study is its case-control design (as opposed to cohort studies) because risk estimates obtained from case-control studies may be biased (referral/selection bias for patients, recall bias for family history) leading to an overestimation of the risk.
However, the odds ratio of 4.6 for heterozygous factor V Leiden, found in our analysis, is in agreement with previously published cohort studies with the pooled odds ratio of 4.5 found in a meta-analysis 41 , which specifically aimed at providing an estimate of the association of factor V Leiden with pregnancy-associated VTE. This result may support the value of our data. While a recall bias might increase the risk estimates for a positive family history of VTE, the multivariate adjustment of thrombophilic risk factors for a positive family history of VTE is likely not influenced. Due to the limitations of the case-control design all results found in our study should be classified as estimations which is evident in the large confidence intervals in the risk calculation of deficiencies of antithrombin, protein C and protein S.
In summary, we demonstrate that unselected women with homozygous factor V Leiden, compound heterozygous factor V Leiden and G20210A prothrombin gene polymorphisms, or severe antithrombin deficiency have a high risk of pregnancy-associated thrombosis, particularly women aged ≥ 35 years. This risk is similar to or higher than the level that would usually trigger prophylactic anticoagulation in the non-pregnant populations (i.e., 3%) 21 .
Whereas carrier status of isolated heterozygous factor V Leiden or G20210A prothrombin gene polymorphism does not require routine thromboprophylaxis in pregnant women, women with the aforementioned types of high-risk thrombophilia may be considered for routine antepartal prophylactic anticoagulation even with a negative family history of VTE.
The question remains whether these findings should lead to a general screening for thrombophilic risk factors in all pregnancies, regardless of family history. Current practical considerations (the cost of general screening vs. the low absolute number of pregnant women who are carriers of the aforementioned mutations and who will develop a venous thromboembolism) lead us to suggest that women with additional thrombophilic risk factors 12 (e.g., obesity) may particularly benefit from a screening. Although a family history is not an indication for heparin prophylaxis in women with the aforementioned mutations, it nevertheless represents such an independent, additional risk factor (see above). In conclusion, we suggest that even though general screening of all pregnancies may be considered ideal to estimate individual risk, this is unlikely to be cost effective, therefore women with additional risk factors should constitute the main focus for selected screening in pregnancy 42;43 .
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